コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 r and to the glycine transporters (GlyT1 and GlyT2).
2 lycine transporter (GlyT) isoforms GlyT1 and GlyT2.
3 interaction between the wild-type and mutant GlyT2.
4 ins 5, 7, and 8, and extracellular loop 4 of GlyT2.
5 uctural alterations of the S512R mutation in GlyT2.
6 other paralog showing greater similarity to GlyT2.
7 and how these bioactive lipids interact with GlyT2.
8 s-311-Cys-320 in the second external loop of GlyT2.
9 ansporter VGluT2 and the glycine transporter GlyT2.
10 igh-affinity glycine transporters, GlyT1 and GlyT2.
11 ansporter VGluT2 and the glycine transporter GlyT2.
12 hile inhibitors of glycine transport through GlyT2 (4-benzyloxy-3,5-dimethoxy-N-[1-(dimethylaminocycl
15 us PMCA and NCX activities are necessary for GlyT2 activity and that this modulation depends on lipid
16 enous regulatory mechanism that can modulate GlyT2 activity based on a compartmentalized interaction
21 for sodium in the absence of substrate than GlyT2 and a gating mechanism that locks Na[Formula: see
22 unohistochemistry combined with ISH for both GlyT2 and GAD-67 mRNAs showed that at least 63% of midli
23 of preBotC inhibitory neurons expressed both GlyT2 and GAD2 while a much smaller subpopulation also e
24 ycine inhibitors, however, are selective for GlyT2 and have been shown to provide analgesia in animal
25 insight into the mechanism of inhibition of GlyT2 and highlights how lipids can modulate the activit
27 We find that the plasma membrane transporter GlyT2 and the intracellular enzyme glutamate decarboxyla
28 acts with the raft-associated active pool of GlyT2, and low and high levels of the specific NKA ligan
29 encoding the presynaptic glycine transporter GlyT2 are a second major cause of human hyperekplexia, a
32 ith the hypothesis that vertebrate GlyT1 and GlyT2 are, respectively, derived from GlyT1- and GlyT2-l
33 nate presynaptic glycine transporter (SLC6A5/GlyT2) are well-established genes of effect in hyperekpl
34 a trend for higher expression of VGLUT1 and GLYT2 around motor neurons in Trained versus Untrained r
38 e middle ear ossicles, caused a reduction in Glyt2, but not Glyt1 mRNA in the ipsilateral DCN and in
45 -mediated transfection of the flexed gene in GlyT2-Cre transgenic mice, evoked fast IPSCs in principa
46 rationalizing its phylogenetic proximity to GlyT2 despite their extreme divergence in specificity.
48 edullary slices from neonatal Dbx1(tdTomato);GlyT2(EGFP) and Dbx1(tdTomato);GAD1(EGFP) double reporte
50 excitability and morphology of glycinergic (GlyT2 expressing) ventral lumbar interneurons from SOD1G
51 c neurons, the neuronal glycine transporter (GLYT2) for glycinergic neurons, and glutamic acid decarb
52 c neurons, the neuronal glycine transporter (GLYT2) for glycinergic neurons, and glutamic acid decarb
53 Overexpression of calnexin rescued wild-type GlyT2 from the dominant negative effect of the mutant, i
54 ough the most common mechanism of disrupting GlyT2 function is protein truncation, new pathogenic mec
59 ic Na(+)/Cl(-)-dependent glycine transporter GlyT2 gene (SLC6A5) are rapidly emerging as a second maj
60 frameshift, and splice site mutations in the GlyT2 gene as the second major cause of startle disease.
61 eurons expressing the glycine transporter 2 (GlyT2) gene coexpress enhanced green fluorescent protein
64 the human SLC6A5 gene encoding the neuronal GlyT2 glycine transporter are responsible for the presyn
69 inant negative effect that retains wild-type GlyT2 in the endoplasmic reticulum (ER), preventing surf
83 proteins constitute an outgroup to both the GlyT2-like proteins and to vertebrate GlyT1 sequences.
85 A5 mutations result in defective subcellular GlyT2 localization, decreased glycine uptake or both, wi
88 the glycine transporters 1 and 2 (GlyT1 and GlyT2)--members of the solute carrier family 6 (SLC6).
95 sequencing of SLC6A5 revealed a new dominant GlyT2 mutation: pY705C (c.2114A-->G) in transmembrane do
97 d on a compartmentalized interaction between GlyT2, neuronal plasma membrane Ca(2+)-ATPase (PMCA) iso
101 where GABAergic (GAD1/2(+)) and glycinergic (GlyT2(+)) neurons are functionally and anatomically inte
109 al domain, dual in situ staining showed that GLYT2-positive cells were intermingled with VGLUT2 cells
111 ore and after chemogenetic downregulation of GlyT2-positive interneurons in male and female mice.
112 results suggest that inhibition mediated by GlyT2-positive interneurons primarily governs the tempor
116 under control of the glycine transporter 2 (GLYT2) regulatory sequences to study for the first time
117 cing revealed three conspicuous pairs of GFP/GLYT2(+) reticular neurons projecting to the spinal cord
118 itors that target the glycine transporter 2, GlyT2, show promise as analgesics, but may be limited by
119 s that inhibit the human glycine transporter GlyT2 (SLC6A5) and provide analgesia in animal models of
120 he SLC6 family along with GlyT1 (SLC6A9) and GlyT2 (SLC6A5), two glycine-specific transporters couple
123 s at embryonic stages were also positive for GLYT2, suggesting that the cells might use both GABA and
124 minal by the neuronal glycine transporter 2 (GlyT2) to maintain quantal glycine content in synaptic v
126 , but had little or no activity at the human GlyT2 transporter, at other binding sites for glycine, o
130 form a monophyletic subclade with vertebrate GlyT2, while invertebrate GlyT1-like proteins constitute